Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
MiniMed Group, Medtronic’s diabetes unit, filed for a U.S. IPO on December 19, 2025, to become an independent public company.
Medtronic’s diabetes unit, MiniMed Group, has filed for a U.S. IPO to become an independent public company, aiming to list on Nasdaq under the ticker "MMED."
The filing, announced on December 19, 2025, marks a key step in Medtronic’s plan to spin off its diabetes business, with proceeds to repay intercompany debt and fund general corporate needs.
MiniMed reported a $21 million net loss on $1.48 billion in sales for the six months ending October 24, 2024, improving from a $23 million loss the prior year.
The IPO, led by major underwriters, is expected to finalize within 18 months, with Medtronic retaining at least 80.1% of voting shares.
The move reflects a broader trend of corporate separations and a revived IPO market, with U.S. offerings raising $75.3 billion in 2025.
MiniMed Group, la unidad de diabetes de Medtronic, solicitó una OPI en los Estados Unidos el 19 de diciembre de 2025, para convertirse en una compañía pública independiente.